1 May 2008 in Clinical Immunology
1 October 2011 in Journal of Advanced Research
Jaccoud’s arthropathy (JA) is a chronic, deforming, non-erosive arthropathy occurring in a subset of patients with systemic lupus erythematosus (SLE). In this research we aimed to evaluate clinical and immunological features in patients with SLE complicated by JA. Eighty seven consecutive SLE patients with a history of arthritis were included in the present study. These patients were subdivided according to “Jaccoud’s arthropathy index” as follows: non-deforming arthropathy, mild deforming and definite Jaccoud. Demographic data, disease activity and disability were recorded. Rheumatoid factor (RF), anti-cardiolipin antibodies (ACL), antiSSA/Ro, and anti SSB/La antibodies, were assessed in all patients. We found clinical deforming arthropathy in 12 patients, among whom seven had definite JA. Both the mean duration of the disease and of arthritis were longer in the JA group compared to the non-deforming arthropathy group. JA patients presented a trend toward a lower quality of life. The prevalence of Sicca syndrome (SS) and antiphospholipid syndrome were significantly higher in the JA group than in the patients with non-deforming arthropathy (p=0.011 and 0.012, respectively). ACL and RF were more frequent among patients with JA (p=0.013 and 0.036; respectively). These data suggest that JA is not rare and represents a subset of SLE with specific clinical and serological features. Future studies are needed to reveal the pathogenesis, the genetic association, the prevention, the stabilization and the appropriate cure for these patients
10 January 2017 in Asian Journal of Medicine and Health
Introduction: Chronic kidney disease (CKD) has become a global public health threat. The irreversible nature of the disease, its association with significant morbidity and mortality as well as the cost of renal replacement therapy leads to a large burden for health care providers, particularly in developing countries like Egypt. Objective: To find a non-invasive method to evaluate association of serum visfatin with chronic kidney disease secondary to diabetic nephropathy and compare to patients with chronic kidney disease secondary to other causes. Methods: Ninety individuals including 30 healthy controls and 60 patients of CKD were included in this study. Patients with CKD were further grouped based on etiology of CKD into 30 diabetic patients and 30 non-diabetic patients. Patients with type 1 diabetes mellitus, urinary tract infection, urolithiasis, liver cirrhosis, stroke, ischemic heart disease, and rheumatoid arthritis were excluded. Measurement of serum visfatin was done through ELISA Kit (Elabscience pharmaceuticals). Results: Visfatin concentration was significantly high in patients with CKD compared to controls (p < 0 .001). No significant difference in Visfatin concentrations between patients of CKD with and without diabetes was detected (p > 0.05). Visfatin concentration was significantly high in patients with CKD stage 2 compared to CKD stage 1 (p < 0 .001). Conclusion: The present study confirms the association of visfatin with CKD, however further studies at molecular level to check its expression within renal tissue may clarify its definitive role in CKD.
10 January 2017 in Asian Journal of Medicine and Health
Poor vitamin D status is frequently linked with nearly all elements of the metabolic syndrome. There is insufficient evidence of beneficial effect to recommend vitamin D supplementation as a means of improving insulin resistance. The aim of this study was to determine the relation between vitamin D deficiency and insulin resistance in patients with metabolic syndrome. Materials and Methods: Ninety patients with metabolic syndrome received 200,000 IU vitamin D intramuscularly every 4 weeks for 12 weeks. Serum 25-hydroxy vitamin D [25(OH)D], fasting blood sugar, Hb A1c, homeostasis model assessment of insulin resistance(HOMA IR), serum lipid profiles anthropometric factors and blood pressure were assessed before and after intervention. Results: After intervention, Serum 25-hydroxy vitamin D [25(OH)D] concentration increased in all subjects (14.5 ± 2.2 vs. 32 ± 5.5 (P .0001)]. There was a significant decrease of HOMA-IR (3.05 ± 0.34 vs 2.08 ± .25(P=0.003) in patients with vitamin D deficiency before supplementation. In conclusion vitamin D supplementation improve IR in patients with metabolic syndrome with vit D deficiency. So, vitamin D supplementation based on baseline [25(OH)D] is recommended.